Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-08-18
2010-11-09
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S04400A, C514S321000, C514S409000, C514S567000, C514S772000
Reexamination Certificate
active
07829535
ABSTRACT:
Methods for promoting osteogenesis to accelerate or enhance bone fracture healing, treat bone defects, and enhance bone formation are disclosed. The methods modulate an arachidonic acid metabolic or signaling pathway in general, and, in particular, utilize 5-lipoxygenase inhibitors. These molecules can be delivered alone or in combination with one or more agents that inhibit bone resorption, regulate calcium resorption from bone, enhance bone accumulation, enhance bone formation, induce bone formation, impair growth of microorganisms, reduce inflammation, and/or reduce pain.
REFERENCES:
patent: 7291638 (2007-02-01), O'Connor
patent: 2003/0175680 (2003-09-01), Allard et al.
patent: 2004/0138262 (2004-07-01), Chantigny et al.
patent: 2005/0032747 (2005-02-01), Bartolini et al.
patent: 2005/0058734 (2005-03-01), Burch et al.
patent: 2008/0033033 (2008-02-01), Kambe et al.
patent: WO 01/41753 (2001-06-01), None
patent: WO 03/020267 (2003-03-01), None
patent: WO 2005/123130 (2005-12-01), None
PCT International Search Report and Written Opinion, PCT/US2006/032367, Jul. 10, 2007, 11 pages.
PCT International Preliminary Report on Patentability, PCT/US2006/032367, Jan. 7, 2008, 12 pages.
Office Action for Israel Patent Application No. 18955, Apr. 21, 2010, 4 pages.
PCT International Search Report and Written Opinion, PCT/US2009/034790, Jul. 23, 2009, 15 pages.
Examination Report, New Zealand Patent Application No. 566283, Feb. 24, 2010, 2 pages.
Supplementary European Search Report, European Patent Application No. EP 06801878, Mar. 17, 2010, 12 pages.
Response to European Search Report and Exhibits A-F, European Patent Application No. EP 06801878, Jun. 16, 2010, 12 pages.
Exhibit E—Abstract for two articles by J.L. Collins (1. Collins, J.W., et al., “The Role of Leukotrienes in Force-induced Bone Development,” Department of Orthodontics, CWRU School of Dentistry, J. Dent. Res., 1987, vol. 66, No. 1722; and 2. Collins, J.W., et al., “Stimulation of Bone Development by Mechanical Stress and Inhibition of Leukotriene Biosynthesis,” Department of Orthodontics, CWRU School of Dentistry, Program of the 65th General Session, International Association for Dental Research Annual Session, American Association for Dental Research, Chicago, 1987, p. 328.), Cariology/Craniofacial, p. 28, filed with European Patent Office for European Patent Application No. 06801878.7 on Jun. 16, 2010.
Exhibit D—List of abstracts of relevant review articles published in 2003-2005, filed with European Patent Office for European Patent Application No. 06801878.7 on Jun. 16, 2010, 5 pages.
Exhibit F—Product data sheet, Enzo Life Sciences, can be retrieved at <URL:http://www.enzolifesciences.com/fileadmin/enzo/BML/ei101.PDF>, and filed with European Patent Office for European Patent Application No. 06801878.7 on Jun. 16, 2010, 1 page.
Bonewald, L., et al., “Mice Lacking 5-Lipoxygenase Have Increased Cortical Bone Thickness,” Advances in Experimental Medicine and Biology, 1997, pp. 299-302, vol. 433, 1997.
Burd, T. A., M. S. Hughes, et al. (2003). “Heterotopic ossification prophylaxis with indomethacin increases the risk of long-bone nonunion.” J Bone Joint Surg Br 85-B(5): 700-705.
Burd, T. A., K. J. Lowry, et al. (2001). “Indomethacin Compared with Localized Irradiation for the Prevention of Heterotopic Ossification Following Surgical Treatment of Acetabular Fractures.” J Bone Joint Surg Am 83(12): 1783-1788.
Collins, J.W., et al., “The Role of Leukotrienes in Force-induced Bone Development,” J. Dent. Res., 1987, p. 328, vol. 66, No. 1772. (Abstract).
Collins, J.W., et al., “Stimulation of Bone Development by Mechanical Stress and Inhibition of Leukotriene Biosynthesis,” J. Dent. Res., 1987, p. 328, vol. 66, No. 1771. (Abstract).
Cottrell, J., O'Connor, J.P., “Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Healing,” Pharmaceuticals, 2010, vol. 3, pp. 1668-1693.
Erdmann, L., et al., “Degradable poly(anhydride ester) implants: effects of localized salicylic acid release on bone,” Biomaterials, 2000, pp. 2507-2512, vol. 21.
Fijn, R., Koorevaar, R. Th. (2003). “Prevention of heterotopic ossification after total hip replacement with NSAIDs.” Parmacy World & Science 25(4): 138-145.
Gerstenfeld, L.C., et al., “Impaired Fracture Healing in the Absence of TNF-┐ Signaling: The Role of TNF-α in Endochondral Cartilage Resorption,” Journal of Bone and Mineral Research, 2003, pp. 1584-1592, vol. 18, No. 9.
Gallwitz, W., et al., “5-Lipoxygenase Metabolites of Arachidonic Acid Stimulate Isolated Osteoclasts to Resorb Calcified Matrices,” The Journal of Biological Chemistry, May 15, 1993, pp. 10087-10094, vol. 268, No. 14.
Harten, R., et al., “Salicylic acid-derived poly(anhydride-esters) inhibit bone resorption and formation in vivo,” J. Biomed. Mat. Res., 2005, pp. 354-362, vol. 72A No. 4.
Hungin, A.P.S., et al., “Nonsteroidal Anti-Inflammatory Drugs: Overused or Underused in Osteoarthritis?,” The American Journal of Medicine, Jan. 8, 2001, pp. 8S-11S, vol. 110(1A).
Koivukangas, A., et al., “Long-Term Administration of Clodronate Does Not Prevent Fracture Healing in Rats,” Clinical Orthopaedics and Related Research, 2003, pp. 268-278, No. 408.
Knelles, D., T. Barthel, et al. (1997). “Prevention of Heterotopic Ossification After Total Hip Replacement: A Prospective, Randomised Study Using Acetysalicyclic Acid, Indomethacin and Fractional or Single-Dose Irradiation.” J Bone Joint Surg Br 79-B(4): 596-602.
Moed, B. R. and D. E. Karges (1994). “Prophylactic Indomethacin for the Prevention of Heterotopic Ossification After Acetabular Fracture Surgery in High-Risk Patients.” Journal of Orthopaedic Trauma 8(1): 34-39.
O'Connor, J.P., et al., “Accelerating Fracture Healing by Manipulating Arachidonic Acid Metabolism,” Orthopaedics, Journal of Bone and Mineral Research, Sep. 2005, p. S353, vol. 20, No. 9, Suppl. 1.
Ren, W., et al., “Effects of Leukrotrienes on Osteoblastic Cell Proliferation,” Calcified Tissue International, 1991, pp. 197-201, vol. 49.
Moed, B. R. and J. W. Maxey (1993). “The Effect of Indomethacin on Heterotopic Ossification Following Acetabular Fracture Surgery.” Journal of Orthopaedic Trauma 7(1): 33-38.
Ritter, M. A. and J. M. Sieber (1985). “Prophylactic Indomethacin for the Prevention of Heterotopic Bone Formation Following Total Hip Arthroplasty.” Clinical Orthopaedics and Related Research 196: 217-225.
Rodan, G., et al., “Osteoporosis And Bisphosphonates,” The Journal of Bone & Joint Surgery, 2003, pp. 8-12, vol. 85-A, Supp. 3.
Rozental, T., et al., “Comparison of Radiographic Fracture Healing in the Distal Radius for Patients on and off Bisphosphonate Therapy,” JHS, Apr. 2009, pp. 595-602, vol. 34A.
Sodemann, B., P.-E. Persson, et al. (1988). “Prevention of Heterotopic Ossification by Nonsteroid Antiinflammatory Drugs After Total Hip Arthroplasty.” Clinical Orthopaedics and Related Research 237: 158-163.
Traianedes, K., et al., “5-Lipxygenase Metabolites Inhibit Bone Formation in Vitro,” Endocrinology Jul. 1998, pp. 3178-3184, vol. 139, No. 7.
Vielpeau, C., J.-M. Joubert, et al. (1999). “Naproxen in the Prevention of Heterotopic Ossification After Total Hip Replacement.” Clinical Orthopaedics and Related Research 369: 279-288.
Accelalox, Inc.
Fenwick & West LLP
Henley, III Raymond J
LandOfFree
Methods for bone treatment by modulating an arachidonic acid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for bone treatment by modulating an arachidonic acid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for bone treatment by modulating an arachidonic acid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4173090